—Review the data and clinical implications when comparing early-onset type 2 diabetes in to early-onset type 1 diabetes. Reviewed by Clifton Jackness, MD, Attending Physician in Endocrinology, Lenox ...

Liver stiffness and severe fibrosis, as measured by FibroScan, are independently linked to type 2 diabetes (T2DM) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), new ...

Researchers in China evaluated 432 patients with HeFH, including 99 with T2DM and 333 without, for prevalence and severity of CAD. Patients in the T2DM group had a greater number of diseased arteries ...

Investigators assessed the predictive value of estimated glucose disposal rate on renal outcomes among patients with type 2 diabetes mellitus. Rapid eGFR decline was found to be associated with an ...

Sodium–glucose co-transporter 2 inhibitor (SGLT2i) therapy fails to lower the risk of new-onset psoriasis among patients with ...

Targeting glucose control and managing cardiovascular (CV) risk factors may prevent future CV events, and have positive downstream impact by reducing costs to healthcare stakeholders.

Findings showed oral semaglutide statistically significantly reduced the risk of MACE by 14% compared with placebo at 4 years. The Food and Drug Administration (FDA) has approved Rybelsus ® ...

To our knowledge this is the first randomized-controlled trial showing a benefit of exergaming for a clinical endpoint and for the quality of life of a disease. In this study we demonstrate a ...

Data from the ONWARDS clinical trial program supported the efficacy of once-weekly insulin icodec-abae compared with daily basal insulin. The Food and Drug Administration (FDA) has approved Awiqli ® ...

Strategies that can help clinicians establish and work toward goals when treating patients with chronic kidney disease to help control disease and prevent progression. Neil B. Minkoff, MD: We’ve ...